174 related articles for article (PubMed ID: 33471519)
1. The Discovery and Development of Thienopyrimidines as Inhibitors of
Mugengana AK; Vita NA; Brown Gandt A; Moran K; Agyapong G; Sharma LK; Griffith EC; Liu J; Yang L; Gavrish E; Hevener KE; LaFleur MD; Lee RE
ACS Infect Dis; 2021 May; 7(5):1044-1058. PubMed ID: 33471519
[TBL] [Abstract][Full Text] [Related]
2. Molecular characterization of benzimidazole resistance in Helicobacter pylori.
Mills SD; Yang W; MacCormack K
Antimicrob Agents Chemother; 2004 Jul; 48(7):2524-30. PubMed ID: 15215104
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo activities of HPi1, a selective antimicrobial against Helicobacter pylori.
Gavrish E; Shrestha B; Chen C; Lister I; North EJ; Yang L; Lee RE; Han A; Williams B; Charnuska D; Coleman K; Lewis K; LaFleur MD
Antimicrob Agents Chemother; 2014 Jun; 58(6):3255-60. PubMed ID: 24687512
[TBL] [Abstract][Full Text] [Related]
4.
Huang Y; Hang X; Jiang X; Zeng L; Jia J; Xie Y; Li F; Bi H
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30936098
[No Abstract] [Full Text] [Related]
5. Armeniaspirol A: a novel anti-Helicobacter pylori agent.
Jia J; Zhang C; Liu Y; Huang Y; Bai Y; Hang X; Zeng L; Zhu D; Bi H
Microb Biotechnol; 2022 Feb; 15(2):442-454. PubMed ID: 33780131
[TBL] [Abstract][Full Text] [Related]
6. Targeting Helicobacter pylori for antibacterial drug discovery with novel therapeutics.
Vita NA; Anderson SM; LaFleur MD; Lee RE
Curr Opin Microbiol; 2022 Dec; 70():102203. PubMed ID: 36156373
[TBL] [Abstract][Full Text] [Related]
7. Epinecidin-1 antimicrobial activity: In vitro membrane lysis and In vivo efficacy against Helicobacter pylori infection in a mouse model.
Narayana JL; Huang HN; Wu CJ; Chen JY
Biomaterials; 2015 Aug; 61():41-51. PubMed ID: 25996410
[TBL] [Abstract][Full Text] [Related]
8. Review of current diagnostic methods and advances in
Pohl D; Keller PM; Bordier V; Wagner K
World J Gastroenterol; 2019 Aug; 25(32):4629-4660. PubMed ID: 31528091
[No Abstract] [Full Text] [Related]
9. Anti-Helicobacter pylori potential of artemisinin and its derivatives.
Goswami S; Bhakuni RS; Chinniah A; Pal A; Kar SK; Das PK
Antimicrob Agents Chemother; 2012 Sep; 56(9):4594-607. PubMed ID: 22687518
[TBL] [Abstract][Full Text] [Related]
10. The oligo-acyl lysyl antimicrobial peptide C₁₂K-2β₁₂ exhibits a dual mechanism of action and demonstrates strong in vivo efficacy against Helicobacter pylori.
Makobongo MO; Gancz H; Carpenter BM; McDaniel DP; Merrell DS
Antimicrob Agents Chemother; 2012 Jan; 56(1):378-90. PubMed ID: 22064541
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and bioevaluation of novel 3,4,5-trimethoxybenzylbenzimidazole derivatives that inhibit Helicobacter pylori-induced pathogenesis in human gastric epithelial cells.
Chang CS; Liu JF; Lin HJ; Lin CD; Tang CH; Lu DY; Sing YT; Chen LY; Kao MC; Kuo SC; Lai CH
Eur J Med Chem; 2012 Feb; 48():244-54. PubMed ID: 22217866
[TBL] [Abstract][Full Text] [Related]
12. Experimentally validated novel inhibitors of Helicobacter pylori phosphopantetheine adenylyltransferase discovered by virtual high-throughput screening.
Cheng CS; Jia KF; Chen T; Chang SY; Lin MS; Yin HS
PLoS One; 2013; 8(9):e74271. PubMed ID: 24040220
[TBL] [Abstract][Full Text] [Related]
13. Optimum duration of regimens for Helicobacter pylori eradication.
Yuan Y; Ford AC; Khan KJ; Gisbert JP; Forman D; Leontiadis GI; Tse F; Calvet X; Fallone C; Fischbach L; Oderda G; Bazzoli F; Moayyedi P
Cochrane Database Syst Rev; 2013 Dec; (12):CD008337. PubMed ID: 24338763
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial activity of ellagic acid against Helicobacter pylori isolates from India and during infections in mice.
De R; Sarkar A; Ghosh P; Ganguly M; Karmakar BC; Saha DR; Halder A; Chowdhury A; Mukhopadhyay AK
J Antimicrob Chemother; 2018 Jun; 73(6):1595-1603. PubMed ID: 29566160
[TBL] [Abstract][Full Text] [Related]
15. Solubility, absorption, and anti-Helicobacter pylori activity of bismuth subnitrate and colloidal bismuth subcitrate: In vitro data Do not predict In vivo efficacy.
Phillips RH; Whitehead MW; Lacey S; Champion M; Thompson RP; Powell JJ
Helicobacter; 2000 Sep; 5(3):176-82. PubMed ID: 10971684
[TBL] [Abstract][Full Text] [Related]
16. Selective killing of the human gastric pathogen Helicobacter pylori by mitochondrial respiratory complex I inhibitors.
Lettl C; Schindele F; Mehdipour AR; Steiner T; Ring D; Brack-Werner R; Stecher B; Eisenreich W; Bilitewski U; Hummer G; Witschel M; Fischer W; Haas R
Cell Chem Biol; 2023 May; 30(5):499-512.e5. PubMed ID: 37100053
[TBL] [Abstract][Full Text] [Related]
17. Dihydrotanshinone I Is Effective against Drug-Resistant Helicobacter pylori
Luo P; Huang Y; Hang X; Tong Q; Zeng L; Jia J; Zhang G; Bi H
Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33318002
[No Abstract] [Full Text] [Related]
18. Solution NMR studies on Helicobacter pylori proteins for antibiotic target discovery.
Lee KY; Lee BJ
Expert Opin Drug Discov; 2016 Jul; 11(7):681-93. PubMed ID: 27216839
[TBL] [Abstract][Full Text] [Related]
19. Clarithromycin and omeprazole as helicobacter pylori eradication therapy in patients with H. pylori-associated gastric disorders.
Markham A; McTavish D
Drugs; 1996 Jan; 51(1):161-78. PubMed ID: 8741237
[TBL] [Abstract][Full Text] [Related]
20. Bactericidal activity of medicinal plants, employed for the treatment of gastrointestinal ailments, against Helicobacter pylori.
Zaidi SF; Yamada K; Kadowaki M; Usmanghani K; Sugiyama T
J Ethnopharmacol; 2009 Jan; 121(2):286-91. PubMed ID: 19041711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
